UK industry blames medicine shortages on parallel trade
This article was originally published in SRA
Executive Summary
The problem of medicine shortages in the UK is not going away, and many pharmacists expect the situation to worsen next year, according to a stock survey by Chemist and Druggist1. The situation will only improve if the government steps in, says the Association of the British Pharmaceutical Industry. The industry says that an increase in parallel trade is the reason behind the shortages.
You may also be interested in...
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.
New HTA Evidence Guidelines In EU Could Spell Trouble For Advanced Therapy Companies
New guidelines that cast doubt over the use of single-arm and non-randomized studies are “discouraging” for rare disease patients and the advanced therapy sector, says ARM, the Alliance for Regenerative Medicines.